TW200607858A - Optimized expression of HPV 31 L1 in yeast - Google Patents
Optimized expression of HPV 31 L1 in yeastInfo
- Publication number
- TW200607858A TW200607858A TW093124870A TW93124870A TW200607858A TW 200607858 A TW200607858 A TW 200607858A TW 093124870 A TW093124870 A TW 093124870A TW 93124870 A TW93124870 A TW 93124870A TW 200607858 A TW200607858 A TW 200607858A
- Authority
- TW
- Taiwan
- Prior art keywords
- hpv31
- yeast
- polynucleotides
- synthetic
- protein
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title abstract 2
- 102000040430 polynucleotide Human genes 0.000 abstract 4
- 108091033319 polynucleotide Proteins 0.000 abstract 4
- 239000002157 polynucleotide Substances 0.000 abstract 4
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 229960005486 vaccine Drugs 0.000 abstract 2
- 208000009608 Papillomavirus Infections Diseases 0.000 abstract 1
- 230000024932 T cell mediated immunity Effects 0.000 abstract 1
- 230000003472 neutralizing effect Effects 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000005030 transcription termination Effects 0.000 abstract 1
- 210000005253 yeast cell Anatomy 0.000 abstract 1
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
Synthetic DNA molecules encoding the HPV31 L1 protein are provided. Specifically, the present invention provides polynucleotides encoding HPV31 L1 protein, wherein said polynucleotides are free from internal transcription termination signals that are recognized by yeast. Also provided are synthetic polynucleotides encoding HPV31 L1 wherein the polynucleotides have been codon-optimized for high level expression in a yeast cell. The synthetic molecules may be used to produce HPV31 virus-like particles (VLPs), and to produce vaccines and pharmaceutical compositions comprising the HPV31 VLPs. The vaccines of the present invention provide effective immunoprophylaxis against papillomavirus infection through neutralizing antibody and cell-mediated immunity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW93124870A TWI334438B (en) | 2004-08-18 | 2004-08-18 | Optimized expression of hpv 31 l1 in yeast |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW93124870A TWI334438B (en) | 2004-08-18 | 2004-08-18 | Optimized expression of hpv 31 l1 in yeast |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW200607858A true TW200607858A (en) | 2006-03-01 |
| TWI334438B TWI334438B (en) | 2010-12-11 |
Family
ID=44211874
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW93124870A TWI334438B (en) | 2004-08-18 | 2004-08-18 | Optimized expression of hpv 31 l1 in yeast |
Country Status (1)
| Country | Link |
|---|---|
| TW (1) | TWI334438B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021013062A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 31 l1 protein |
-
2004
- 2004-08-18 TW TW93124870A patent/TWI334438B/en not_active IP Right Cessation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021013062A1 (en) * | 2019-07-19 | 2021-01-28 | 神州细胞工程有限公司 | Chimeric human papillomavirus type 31 l1 protein |
Also Published As
| Publication number | Publication date |
|---|---|
| TWI334438B (en) | 2010-12-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO2018010I1 (en) | HPV 31 L1 protein | |
| EP1687329B8 (en) | Optimized expression of hpv 58 l1 in yeast | |
| MY140664A (en) | Optimized expression of hpv 45 l1 in yeast | |
| MY148656A (en) | Optimized expression of hpv 52 l1 in yeast. | |
| WO2008034388A8 (en) | Virus-like particles of capsid proteins from human papillomavirus type 16/58/18/6/11 and the method for preparation and the uses thereof | |
| WO2010118424A3 (en) | Papillomavirus-like particles (vlp) as broad spectrum human papillomavirus (hpv) vaccines | |
| WO2011146933A3 (en) | Universal dengue virus sequences and methods of use | |
| GB0417430D0 (en) | A novel HPV vaccine comprising peptides from host cell proteins | |
| TW200607858A (en) | Optimized expression of HPV 31 L1 in yeast | |
| MY138895A (en) | Optimized expression of hpv 31 l1 in yeast | |
| EP1427443A4 (en) | VACCINE USING VIRUS VIRUS-ADJUSTED PAPILLOMA VIRUS PROTEINS | |
| SG153837A1 (en) | Vaccine against hpv16 and hpv18 and at least another hpv type selected from hpv 31, 45 or 52 | |
| AR045249A1 (en) | OPTIMIZED EXPRESSION OF HPV 31 L1 IN YEAST | |
| EA200702077A1 (en) | VACCINE | |
| WO2003090664A3 (en) | Mutated hpv-16 e7 polypeptide, pharmaceutical composition comprising it and its preparation process |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4A | Expiration of patent term of an invention patent |